March 1, 2022Open Access

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

Key points are not available for this paper at this time.

National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, National Institutes of Health (USA).

KI fragen

Bookmark

View Full Paper

Cite This Study

Pitisuttithum et al. (Tue,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper